Cargando…
Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial
The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664114/ https://www.ncbi.nlm.nih.gov/pubmed/37843230 http://dx.doi.org/10.4103/1673-5374.382104 |
_version_ | 1785138545927651328 |
---|---|
author | Li, Xiangjun Li, Chunyan Huang, Hai Bai, Dan Wang, Jingyi Chen, Anqi Gong, Yu Leng, Ying |
author_facet | Li, Xiangjun Li, Chunyan Huang, Hai Bai, Dan Wang, Jingyi Chen, Anqi Gong, Yu Leng, Ying |
author_sort | Li, Xiangjun |
collection | PubMed |
description | The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation. However, although the macular thickness can be normalized with each of these two therapies used alone, the vision does not improve in many patients. This might result from the incomplete recovery of retinal ganglion cell injury. Therefore, a prospective, non-randomized, controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery. In this trial, 150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods, followed by treatment with anti-vascular endothelial growth factor drugs, laser photocoagulation therapy, and their combination. All patients will be followed up for 12 months. The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment. The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1, 3, 6, and 9 months after treatment, retinal nerve fiber layer thickness, best-corrected visual acuity, macular area thickness, and choroidal thickness before and 1, 3, 6, 9, and 12 months after treatment. Safety measure is the incidence of adverse events at 1, 3, 6, 9, and 12 months after treatment. The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period. The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity. The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No. (2023)(26) on April 25, 2023, and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2300072478, June 14, 2023, protocol version: 2.0). |
format | Online Article Text |
id | pubmed-10664114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106641142023-09-04 Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial Li, Xiangjun Li, Chunyan Huang, Hai Bai, Dan Wang, Jingyi Chen, Anqi Gong, Yu Leng, Ying Neural Regen Res Research Article The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation. However, although the macular thickness can be normalized with each of these two therapies used alone, the vision does not improve in many patients. This might result from the incomplete recovery of retinal ganglion cell injury. Therefore, a prospective, non-randomized, controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery. In this trial, 150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods, followed by treatment with anti-vascular endothelial growth factor drugs, laser photocoagulation therapy, and their combination. All patients will be followed up for 12 months. The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment. The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1, 3, 6, and 9 months after treatment, retinal nerve fiber layer thickness, best-corrected visual acuity, macular area thickness, and choroidal thickness before and 1, 3, 6, 9, and 12 months after treatment. Safety measure is the incidence of adverse events at 1, 3, 6, 9, and 12 months after treatment. The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period. The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity. The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No. (2023)(26) on April 25, 2023, and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2300072478, June 14, 2023, protocol version: 2.0). Wolters Kluwer - Medknow 2023-09-04 /pmc/articles/PMC10664114/ /pubmed/37843230 http://dx.doi.org/10.4103/1673-5374.382104 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Research Article Li, Xiangjun Li, Chunyan Huang, Hai Bai, Dan Wang, Jingyi Chen, Anqi Gong, Yu Leng, Ying Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title | Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title_full | Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title_fullStr | Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title_full_unstemmed | Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title_short | Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
title_sort | anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664114/ https://www.ncbi.nlm.nih.gov/pubmed/37843230 http://dx.doi.org/10.4103/1673-5374.382104 |
work_keys_str_mv | AT lixiangjun antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT lichunyan antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT huanghai antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT baidan antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT wangjingyi antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT chenanqi antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT gongyu antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial AT lengying antivascularendothelialgrowthfactordrugscombinedwithlaserphotocoagulationmaintainretinalganglioncellintegrityinpatientswithdiabeticmacularedemastudyprotocolforaprospectivenonrandomizedcontrolledclinicaltrial |